These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 32236392)

  • 21. Alzheimer's disease research: the future of BACE inhibitors.
    Burki T
    Lancet; 2018 Jun; 391(10139):2486. PubMed ID: 29976459
    [No Abstract]   [Full Text] [Related]  

  • 22. Cognitive Go/No-Go decision-making criteria in Alzheimer's disease drug development.
    Wessels AM; Edgar CJ; Nathan PJ; Siemers ER; Maruff P; Harrison J
    Drug Discov Today; 2021 May; 26(5):1330-1336. PubMed ID: 33486115
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New evidence for dual binding site inhibitors of acetylcholinesterase as improved drugs for treatment of Alzheimer's disease.
    Zueva I; Dias J; Lushchekina S; Semenov V; Mukhamedyarov M; Pashirova T; Babaev V; Nachon F; Petrova N; Nurullin L; Zakharova L; Ilyin V; Masson P; Petrov K
    Neuropharmacology; 2019 Sep; 155():131-141. PubMed ID: 31132435
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Editorial: Can Digital Technology Advance the Development of Treatments for Alzheimer's Disease?
    Mc Carthy M; Schueler P
    J Prev Alzheimers Dis; 2019; 6(4):217-220. PubMed ID: 31686090
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Commentary: Treating Alzheimer's Disease : Combine or Fail ?
    Bakchine S
    J Prev Alzheimers Dis; 2019; 6(3):174-176. PubMed ID: 31062828
    [No Abstract]   [Full Text] [Related]  

  • 26. Advances in developing novel therapeutic strategies for Alzheimer's disease.
    Cao J; Hou J; Ping J; Cai D
    Mol Neurodegener; 2018 Dec; 13(1):64. PubMed ID: 30541602
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Heterogeneity of Alzheimer's disease: consequence for drug trials?
    Devi G; Scheltens P
    Alzheimers Res Ther; 2018 Dec; 10(1):122. PubMed ID: 30567585
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alzheimer's disease: future drug development and the blood-brain barrier.
    Pardridge WM
    Expert Opin Investig Drugs; 2019 Jul; 28(7):569-572. PubMed ID: 31155971
    [No Abstract]   [Full Text] [Related]  

  • 29. Functional Magnetic Resonance Imaging in Alzheimer' Disease Drug Development.
    Holiga S; Abdulkadir A; Klöppel S; Dukart J
    Methods Mol Biol; 2018; 1750():159-163. PubMed ID: 29512071
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Global issues in drug development for Alzheimer's disease.
    Doody RS; Cole PE; Miller DS; Siemers E; Black R; Feldman H; Schindler R; Graham S; Heath T; Khachaturian AS; Evans R; Carrillo MC
    Alzheimers Dement; 2011 Mar; 7(2):197-207. PubMed ID: 21414556
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alzheimer's disease: clinical trials and drug development.
    Mangialasche F; Solomon A; Winblad B; Mecocci P; Kivipelto M
    Lancet Neurol; 2010 Jul; 9(7):702-16. PubMed ID: 20610346
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lessons Learned from Alzheimer Disease: Clinical Trials with Negative Outcomes.
    Cummings J
    Clin Transl Sci; 2018 Mar; 11(2):147-152. PubMed ID: 28767185
    [No Abstract]   [Full Text] [Related]  

  • 33. The National Institute on Aging and the Alzheimer's Association Research Framework for Alzheimer's disease: Perspectives from the Research Roundtable.
    Knopman DS; Haeberlein SB; Carrillo MC; Hendrix JA; Kerchner G; Margolin R; Maruff P; Miller DS; Tong G; Tome MB; Murray ME; Nelson PT; Sano M; Mattsson N; Sultzer DL; Montine TJ; Jack CR; Kolb H; Petersen RC; Vemuri P; Canniere MZ; Schneider JA; Resnick SM; Romano G; van Harten AC; Wolk DA; Bain LJ; Siemers E
    Alzheimers Dement; 2018 Apr; 14(4):563-575. PubMed ID: 29653607
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reconsideration of Anticholinesterase Therapeutic Strategies against Alzheimer's Disease.
    Wang H; Zhang H
    ACS Chem Neurosci; 2019 Feb; 10(2):852-862. PubMed ID: 30521323
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Searching for Alzheimer's disease therapies.
    Stower H
    Nat Med; 2018 Jul; 24(7):894-897. PubMed ID: 29988132
    [No Abstract]   [Full Text] [Related]  

  • 36. Will We Have a Drug for Alzheimer's Disease by 2030? The View From Pharma.
    Lovestone S; Manji HK
    Clin Pharmacol Ther; 2020 Jan; 107(1):79-81. PubMed ID: 31758815
    [No Abstract]   [Full Text] [Related]  

  • 37. Triple GLP-1/GIP/glucagon receptor agonists, a potential novel treatment strategy in Alzheimer's disease.
    Camins A; Ettcheto M; Busquets O; Manzine PR; Castro-Torres RD; Beas-Zarate C; Verdaguer E; Sureda FX; Bulló M; Olloquequi J; Auladell C; Folch J
    Expert Opin Investig Drugs; 2019 Jan; 28(1):93-97. PubMed ID: 30480461
    [No Abstract]   [Full Text] [Related]  

  • 38. Considerations for future tau-targeted therapeutics: can they deliver?
    Noble W; Jimenez-Sanchez M; Perez-Nievas BG; Hanger DP
    Expert Opin Drug Discov; 2020 Mar; 15(3):265-267. PubMed ID: 31661994
    [No Abstract]   [Full Text] [Related]  

  • 39. New drug treatment for Alzheimer's disease. Information from unpublished trials should be made available.
    Johnstone P
    BMJ; 1998 Oct; 317(7163):946. PubMed ID: 9841010
    [No Abstract]   [Full Text] [Related]  

  • 40. Editorial: The Clinical Trials Alzheimer's Disease (CTAD) Meeting in San Francisco, Fall 2022, Will Be a Very Exciting Event!
    Weiner MW
    J Prev Alzheimers Dis; 2022; 9(3):387. PubMed ID: 35841238
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.